<- Go Home
Precipio, Inc.
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Market Cap
$47.4M
Volume
12.6K
Cash and Equivalents
$2.7M
EBITDA
$231.0K
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$10.7M
Profit Margin
44.52%
52 Week High
$29.80
52 Week Low
$5.45
Dividend
N/A
Price / Book Value
3.25
Price / Earnings
-117.51
Price / Tangible Book Value
12.99
Enterprise Value
$48.4M
Enterprise Value / EBITDA
91.16
Operating Income
-$1.2M
Return on Equity
2.72%
Return on Assets
-3.92
Cash and Short Term Investments
$2.7M
Debt
$3.7M
Equity
$14.6M
Revenue
$24.0M
Unlevered FCF
$252.7K
Sector
Health Care Providers and Services
Category
N/A